Xencor to Present at Upcoming Investor Conferences

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, announced participation in two investor conferences.

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/19/2021 - 04:01 PM

MONROVIA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate at two upcoming investor conferences:

Piper Sandler 33rd Annual Virtual Healthcare Conference
Presentation Available: Monday, November 22, 2021, 10:00 a.m. EST / 7:00 a.m. PST

Evercore ISI 4th Annual HealthconX Conference
Presentation Date: Wednesday, December 1, 2021, 1:00 p.m. EST / 10:00 a.m. PST

Webcasts of the presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. A replay of the live Evercore ISI presentation will be posted on the Xencor website approximately one hour after the live event. Both presentations will be available on the website for at least 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb^® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211119005693/en/

Charles Liles
cliles@xencor.com

Media Contact
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com

Source: Xencor, Inc.

Keep reading

More on XNCR

Sep 2, 2026 Xencor to Present at the 2026 Cantor Global Healthcare Conference
Aug 5, 2026 Xencor Reports Second Quarter 2026 Financial Results
Jul 29, 2026 Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

All XNCR news

Trending in the feed

ARGX

argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease Open the live feed